Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.60 |
| ▸ | KDM6B | O15054 | 1/20 | 0.60 |
| ▸ | KDM5C | P41229 | 1/20 | 0.60 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.60 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29584593 | 1.00 | KDM4E (0.60) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| Hydrochloric Acid SCHEMBL40566 | 0.98 | KDM4E (0.58) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL31705352 | 0.83 | KDM4E (0.45) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL16107675 | 0.82 | KDM4E (0.66) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| Hydrochloric Acid SCHEMBL582012 | 0.82 | KDM4E (0.53) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL23380278 | 0.82 | KDM4E (0.51) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL29587235 | 0.81 | KDM4E (0.61) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL17761 | 0.81 | KDM4E (0.61) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL70279 | 0.81 | KDM4E (0.86) | KDM4EKDM4CKDM6BKDM5CKDM2A | |
| SCHEMBL29894587 | 0.81 | KDM4E (0.86) | KDM4EKDM4CKDM6BKDM5CKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 636 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850244-B | Preparation method of topiroxostat | 成都大学 | 2023-05-16 | — | — | CN | claimed |
| CN-115850244-A | Preparation method of topiroxostat | 成都大学 | 2023-03-28 | — | — | CN | claimed |
| EP-4747245-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260076962-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | NIMMUNE BIOPHARMA, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2026-01-29 | — | — | US | disclosed |
| US-12521393-B2 | Cytotoxicity targeting chimeras for CCR2-expressing cells | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-13 | — | — | US | disclosed |
| US-12502388-B2 | Lanthionine synthetase C-like 2-based therapeutics | NIMMUNE BIOPHARMA, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| WO-2004045508-A2 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-6743802-B2 | ASTHMA THERAPY; ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2004-06-01 | — | — | US | disclosed |
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
| EP-1397359-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-03-17 | — | — | EP | disclosed |
| US-6677351-B2 | USEFUL IN TREATMENT OF ASTHMA AND INFLAMMATION | MERCK FROSST CANADA & CO. (CA) | 2004-01-13 | — | — | US | disclosed |
| US-20030114478-A1 | Alkyne-aryl phosphodiesterase-4 inhibitors | MERCK CANADA INC. (CA) | 2003-06-19 | — | — | US | disclosed |
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-05-22 | — | — | US | disclosed |
| WO-2003018579-A1 | ALKYNE-ARYL PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-03-06 | — | — | WO | disclosed |
| WO-2002094823-A1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | KDM4E 3048/4885KDM4C 2357/4885KDM6B 2206/4885 |
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | KDM4E 390/4885KDM4C 549/4885KDM6B 260/4885 |
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | PDE4B, PDE4A, PDE5A | KDM4E 467/4885KDM4C 382/4885KDM6B 730/4885 |
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE7A | KDM4E 1159/4885KDM4C 1350/4885KDM6B 2836/4885 |
| US-12502388-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANCL2, CBS, LCP2 | KDM4E 3829/4885KDM4C 4045/4885KDM6B 3640/4885 |
| US-20030114478-A1 | Alkyne-aryl phosphodiesterase-4 inhibitors | PDE4A, PDE3B, PDE4B | KDM4E 318/4885KDM4C 315/4885KDM6B 436/4885 |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | KDM4E 3335/4885KDM4C 1308/4885KDM6B 1070/4885 |
| US-20260076962-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | SCLY, CLCN2, CBS | KDM4E 2045/4885KDM4C 2223/4885KDM6B 1893/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | KDM4E 2304/4885KDM4C 2717/4885KDM6B 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.